Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)
‘Breast cancer’ defines a malignant tumor that has developed from cells in the breast. Some breast cancers are called in situ as they are confined within the ducts (ductal carcinoma in situ or DCIS) or lobules (lobular carcinoma in situ or LCIS) where they originated. Although, less commonly, breast cancer can also instigate in the stromal tissues, which includes the fatty and fibrous connective tissues of the breast. In the early stages, breast cancer may not cause any symptoms. A lump may be too small to feel or to cause any unusual changes that could be noticed on own. Typically, an abnormal area shows up on a screening mammogram which leads to further testing. Several risk factors including smoking and alcohol consumption, exposure to estrogen, gender, age, family history and personal history are linked to the growth of breast cancer.
The global breast cancer market is likely to grow strongly in the coming years driven by rising healthcare expenditure, rising diabetic and obese population, increasing consumption of alcohol and tobacco and rising female population above 65 years of age. Key trends of the market includes rising development of PARP inhibitors, increasing adoption of minimally invasive procedures and rising awareness programs and research grants. However, growth of the market can be hindered by several factors including financial burden of breast cancer, drug development challenges in developing countries, long term side effects of drugs.
The report “Global Breast Cancer Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and APAC regions along with the global market. The report profiles the key players of the market including Johnson & Johnson, AbbVie, AstraZeneca and Roche.